Septerna to Participate in Upcoming Investor and Industry Conferences
22 Feb 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Septerna, Inc., a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that members of the management team, including Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder, and Liz Bhatt, MS, MBA, Chief Operating Officer, will participate in the following investor and industry conferences:
Evercore ISI 2024 Emerging Private Biotech Conference
Presentation: Wednesday, February 28, 2024, at 2:50 p.m. ET.
Location: Virtual.
TD Cowen 44th Annual Health Care Conference
Participation: Monday, March 4, 2024.
Location: Boston, MA.
Fierce Biotech 2024 Business Development and Licensing Summit
Panel: “Dynamics and Structures for Negotiating and Evaluating Platform Deals” on Monday, March 11, 2024, at 1:15 p.m. PT.
Location: San Francisco, CA.
Leerink Partners 2024 Global Biopharma Conference
Participation: Wednesday, March 13, 2024.
Location: Miami, FL.
About Septerna
Septerna, Inc. is a biotechnology company focused on advancing novel, oral small molecule medicines targeting the entire class of G protein-coupled receptors (GPCRs). The company’s Native Complex Platform™ recapitulates GPCRs with their native structure, function, and dynamics outside of the cellular environment to rapidly apply new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. Septerna was launched in 2022 by scientific founders who have made groundbreaking GPCR discoveries. For more information, please visit .
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.